2024-10-25 - Analysis Report
## Pfizer Inc. (PFE) Stock Analysis Report 

**1. Performance and Comparison:**

Pfizer Inc. (PFE) is a pharmaceutical company that develops and manufactures medicines and vaccines.

As of the latest data, PFE's cumulative return is -12.82%, significantly lagging behind the S&P 500 (VOO) which has a cumulative return of 135.48%. The divergence between PFE and VOO is -148.3, placing it at the 87th percentile of its historical range. This suggests PFE has significantly underperformed compared to the broader market.

**2. Recent Price Movement:**

* **Closing price:** 28.64 (Post-market: 28.65)
* **5-day moving average:** 28.89
* **20-day moving average:** 29.07
* **60-day moving average:** 29.10

PFE's current price is below its recent moving averages, indicating a potential downtrend in the short term.

**3. Technical Indicators:**

* **RSI:** 50.67
* **PPO:** -0.22
* **Delta_Previous_Relative_Divergence:** +0.87 (short-term upward trend)
* **Expected Return:** 0.0% (long-term expected return compared to S&P 500)

The RSI indicates PFE is in a neutral territory, while the PPO suggests a possible bearish trend. The positive Delta_Previous_Relative_Divergence suggests a short-term upward momentum. However, the expected return is currently 0%, suggesting a potential for underperformance compared to the S&P 500 in the long term.

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-30 | 0.6 | 0.458 |
| 2024-05-01 | 0.82 | 0.516 |
| 2024-01-30 | 0.1 | -0.19 |
| 2023-10-31 | -0.17 | -0.32 |
| 2023-08-01 | 0.67 | 0.56 |

PFE has been consistently beating earnings expectations in recent quarters. The latest earnings report for Q2 2024 showed an EPS of 0.6, exceeding the expected EPS of 0.458. This positive earnings trend suggests potential for future growth, but further monitoring of earnings and guidance is necessary.

**5. News and Recent Developments:**

* **Recent Earnings News:**  You can find recent earnings news related to Pfizer on platforms like Shacknews, Seeking Alpha, and Yahoo Finance. 
* **Market Outlook:**  Analysts at FINBOLD currently hold a "Hold" rating on PFE, highlighting its potential for stability but not significant growth. They emphasize the need for further observation of its performance and long-term strategic direction.

**6. Overall Analysis:**

PFE is currently underperforming the broader market, with a negative cumulative return and a significant divergence from the S&P 500. However, the recent earnings beat and positive technical indicators suggest a potential for short-term upward momentum. Nevertheless, the long-term expected return remains neutral, suggesting caution regarding significant outperformance compared to the market. 

**7. Recommendation:**

Given the current market conditions and PFE's performance, investors should exercise caution. While the recent earnings beat provides some optimism, the overall performance and long-term expectations suggest that PFE may not be a significant growth opportunity in the near future. It is important to monitor further earnings releases, analyst opinions, and overall market trends before making investment decisions. 
